Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care – invasive surgery – according to research from a phase III randomized international study.
from Today's Healthcare News -- ScienceDaily http://ift.tt/1PkwMrG
No comments:
Post a Comment